Why might a patient be referred for immunotherapy instead of chemotherapy?

Why might a patient be referred for immunotherapy instead of chemotherapy?

• A. They prefer less aggressive treatment options
• B. They have tumors expressing specific immune targets or markers
• C. They have previously failed chemotherapy
• D. They are not eligible for surgery

Answer: (B)

The referral of a patient for immunotherapy instead of chemotherapy is often based on the presence of specific immune targets or markers expressed by their tumors. Immunotherapy works by enhancing the body’s immune response against cancer cells, which can be particularly effective for tumors that have certain characteristics, such as high levels of PD-L1 (a protein that helps tumors evade immune detection) or specific genetic mutations. These immune targets can indicate that the tumor is more likely to respond positively to immunotherapy. Choosing immunotherapy may also be influenced by the biological behavior of the cancer; for example, certain types of cancers, like melanoma or non-small cell lung cancer, have shown significant responsiveness to immunotherapeutic agents based on these markers. By identifying patients who possess these molecular characteristics, healthcare providers can tailor treatment plans that are more likely to be effective for individual patients, marking a shift towards personalized medicine in oncology.

The referral of a patient for immunotherapy instead of chemotherapy is often based on the presence of specific immune targets or markers expressed by their tumors. Immunotherapy works by enhancing the body’s immune response against cancer cells, which can be particularly effective for tumors that have certain characteristics, such as high levels of PD-L1 (a protein that helps tumors evade immune detection) or specific genetic mutations. These immune targets can indicate that the tumor is more likely to respond positively to immunotherapy.

Choosing immunotherapy may also be influenced by the biological behavior of the cancer; for example, certain types of cancers, like melanoma or non-small cell lung cancer, have shown significant responsiveness to immunotherapeutic agents based on these markers. By identifying patients who possess these molecular characteristics, healthcare providers can tailor treatment plans that are more likely to be effective for individual patients, marking a shift towards personalized medicine in oncology.